Table 3.

Breast cancer clinical trials involving miRs.

Trial reference	Study type	Sponsor	Trial title
NCT1722851	Observational	Cancer Trials Ireland	Circulating miRNAs: novel breast cancer biomarkers and their use for guiding and monitoring response to chemotherapy
NCT2127073	Interventional	Sheldon Feldman	Pilot study of oxytocin and microRNA identification in NAF, serum, and tissue in women with breast cancer
NCT1957332	Observational	University Medical Center Groningen	Imaging patients for cancer drug selection – metastatic breast cancer (IMPACT-MBC)
NCT1598285	Observational	Spanish Breast Cancer Research Group	A combined GWAS and miRNA for the Identification of bevacizumab response predictors in metastatic breast cancer
NCT1231386	Observational	City of Hope Medical Center	miRNAs profiling of breast cancer in patients undergoing neoadjuvant or adjuvant treatment for locally advanced and inflammatory breast cancer
NCT1612871	Interventional	Institut Claudius Regaud	Circulating miRNAs as biomarkers of hormone sensitivity in breast cancer? Pilot study
NCT2656589	Observational	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	A perspective study of the predictive value of microRNA in patients with HER2 positive advanced stage breast cancer who were treated with herceptin
NCT2065908	Observational	West Pomeranian Cancer Center	Circulating microRNAs as a novel biomarker of early cardiotoxicity in breast cancer patients treated with anthracyclines
NCT581750	Observational	Memorial Sloan Kettering Cancer Center	Molecular genetic basis of invasive breast cancer risk associated with lobular carcinoma in situ
NCT1965522	Interventional	Juravinski Cancer Center	Anti-proliferative effects of vitamin D and melatonin in breast cancer (MELO-D)
NCT2288806	Interventional	Hamilton Health Sciences Corporation	Melatonin and vitamin d in breast cancer (MELO-D)
NCT2103140	Interventional	Georgetown University	An exercise randomized controlled trial targeting African-American women with metabolic syndrome and high risk for breast cancer
NCT1907438	Observational	Hadassah Medical Organization	Identification of the transformation potential of normal estrogen exposed BRCA1 (breast cancer susceptibility gene 1) and BRCA2 (breast cancer susceptibility gene 2) heterozygous epithelial breast cells due to irradiation
NCT773695	Interventional	Hoffmann-La Roche	A multicenter, randomized, ph II clinical trial to evaluate the effect of avastin in combination with neoadj treatment regimens on the molecular and metabolic characteristics and changes in the primary tumors with ref to the obtained responses in patients with large primary HER2 Neg breast cancers
NCT1724450	Interventional	University of Sao Paulo	Carvedilol effect in preventing chemotherapy – induced cardiotoxicity. a randomized double blind study
NCT2437318	Interventional	Novartis Pharmaceuticals	A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment
NCT1879436	Observational	Meir Medical Center	The effect of human placental explants and pregnant women sera on cancer cells
NCT2678650	Interventional	Capital Medical University	MicroRNA mediates volatile anesthetics preconditioning induced artery protection